Triveni Bio Doses First Patient in Global Phase 2 Proof-of-Concept Study of TRIV-573 in Atopic Dermatitis and Provides I&I Pipeline Update

— TRIV-573, potential first-in-class KLK5/7 x IL-13 bispecific, simultaneously targets skin barrier dysfunction and inflammation to address fundamental drivers of disease — Company also announces the completion of a strategic transaction to advance the development of TRIV-920 potential first-in-class monoclonal antibody — Pipeline progress highlights continued execution across clinical and preclinical portfolio WATERTOWN, Mass., October […] The post Triveni Bio Doses First Patient in Global Phase 2 Proof-of-Concept Study of TRIV-573 in Atopic Dermatitis and Provides I&I Pipeline Update appeare